Comparative Pharmacology
Head-to-head clinical analysis: RITODRINE HCL versus RITODRINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RITODRINE HCL versus RITODRINE HYDROCHLORIDE.
RITODRINE HCL vs RITODRINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-2 adrenergic receptor agonist; stimulates beta-2 receptors in uterine smooth muscle, causing relaxation and inhibiting uterine contractions. Also has some beta-1 activity at higher doses.
Beta-2 adrenergic receptor agonist; stimulates beta-2 receptors in uterine smooth muscle, causing relaxation and inhibiting uterine contractions.
10 mg orally every 2 hours for preterm labor; initially 50-100 mcg/min IV, titrated to response, maximum 350 mcg/min.
Intravenous: Initial 0.1 mg/min, increased by 0.05 mg/min every 10-15 min until contractions cease or intolerance; max 0.35 mg/min. Oral: 10-20 mg every 2-4 hours, start 30 min before IV discontinuation.
None Documented
None Documented
Terminal elimination half-life: 15-17 hours in pregnant women; 2-4 hours in non-pregnant adults. Context: Half-life prolonged in pregnancy due to increased Vd and decreased clearance.
Terminal elimination half-life: 1.7-2.6 hours (mean 2.0 h) in pregnant women; prolonged in renal impairment.
Renal: 70-90% as unchanged drug and metabolites. Biliary/fecal: 10-30%.
Renal: 70-90% as unchanged drug and metabolites (mainly glucuronide and sulfate conjugates); biliary/fecal: minor (<10%).
Category C
Category C
Tocolytic Agent
Tocolytic Agent